Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Dci Group (GILD) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Dci Group (GILD) lobbying for?
The following is a summary of the lobbying data provided:
– Lobbying Firms Hired: The Mcmanus Group, W Strategies, Llp, Capitol Tax Partners, Tarplin, Inc., Gilead Sciences, The Duberstein Group Inc., Llc, Todd Strategy Group, Downs & Young, Akin Gump Strauss Hauer & Feld, Farragut Partners Llp, Tiber Creek Group
– General Issues Lobbied On: Taxation/Internal Revenue Code, Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign), Budget/Appropriations
– Specific Issues Lobbied On: Consolidated Appropriations Act, oncology products, Hepatitis C, patent rights and funding, HIV and oncology portfolio, triple negative breast cancer (TNBC) and early detection and screenings for breast cancer, pharmaceutical policy as it relates to payments under the 340B program, diversity in clinical trials, developing treatments for COVID-19, Inflation Reduction Act, CREATES Act, PEPFAR, public health initiatives around opioids and infectious diseases, waiver of intellectual property rights for COVID therapeutics and diagnostics, HCV Screening, legislative and regulatory proposals to change international and domestic corporate tax law and policy, expanding access to HIV treatment and prevention therapies, Ryan White Care Act reauthorization, Medicaid Value Based Payment rule, Medicare Part D reform and benefit redesign, CMS rules related to Notice of Benefit and Payment Parameters (NBPP), HCV policy issues, resea.
One could infer that Gilead Sciences is lobbying on these issues to protect the interests of its business operations, primarily related to healthcare, pharmaceuticals, and patents. For instance, the company may be advocating for policies that support funding for research and development of drugs, streamlining patent and trademark applications, and ensuring access and reimbursement for its products, such as HIV and COVID-19 treatments, oncology products, and Hepatitis C drugs. The company may also be engaging with government agencies and decision-makers to influence policies related to drug pricing, Medicare/Medicaid, and tax laws.
